- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05073666
Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event (PACTE)
Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event The PACTE Registry
Venous thromboembolic disease (VTE) is a common clinical entity whose two manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). After an acute PE, almost half of the patients complain residual dyspnea, despite well-conducted curative anticoagulation. Some will present persistent defects on lung scan-scintigraphy, without pulmonary hypertension. This condition defines Chronic-Thrombo-Embolic Disease(CTED). The prevalence of CTED after PE is poorly known as are its risk factors.
The primary objective is to determine the prevalence of CTED at 3 or 6 months, depending on the provoked or unprovoked character, after a PE.
The secondary objectives are:
- To determine the potential risk factors for the occurrence of CTED.
- To look for an association between the persistence of DVT and the occurrence of CTED.
- To look for an association between the diagnosis of CTED and PE recurrence during the 12-month follow-up.
- To determine the diagnostic performance of the clinician alone compared to the lung scintigraphy (gold standard) for the diagnosis of CTED.
- To compare the impact on the quality of life (QoL) with or without CTED.
- To determine the correlation between impaired QoL and the degree of residual obstruction on lung scintigraphy.
Visão geral do estudo
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Contato de estudo
- Nome: emile ferrari
- Número de telefone: 33492037735
- E-mail: ferrari.e@chu-nice.fr
Locais de estudo
-
-
-
Nice, França, 06000
- Recrutamento
- Nice University Hospital
-
Contato:
- emile ferrari
- Número de telefone: 33492037735
- E-mail: ferrari.e@chu-nice.fr
-
Investigador principal:
- Emile Ferrari
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- definite PE with expected life expectancy of more than 3 months - Age ≥ 18 years old.
- Patients with a first episode of symptomatic pulmonary embolism, diagnosed by CT angiography or pulmonary scintigraphy and treated in a conventional manner.
- Having received oral information about the study and having expressed a non-opposition to participate to the study
- Benefiting from a social security scheme
Exclusion Criteria:
- Patients with pulmonary hypertension.
- Patients who have already had a recurrence of pulmonary embolism or deep vein thrombosis of the lower limbs.
- Patients with a contraindication to performing a lung ventilation-perfusion scintigraphy.
- Patients at high risk of recurrence of venous thromboembolic disease (severe thrombophilia or active cancer).
- Classical contraindications to anticoagulants.
- Vulnerable patients: pregnant women, under guardianship or curatorship
- Premature termination of participation
- Recurrent pulmonary embolism diagnosed by CT angiography, or deep vein thrombosis diagnosed by venous Doppler ultrasound of the lower limbs within the first 3 or 6 months depending on the nature of the VTE.
- Occurence of pulmonary hypertension detected by trans-thoracic ultrasound (systolic pulmonary arterial pressure more than 35 mmgh).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
---|---|
pulmonary embolism
Patients with a recent pulmonary embolism event will be followed for 6 months and will benefit of routine tests (Lung scintigraphy, venous echo doppler, d- dimers measurement) in order to determine chronic thrombo-embolic disease prevalence and its risk factors.
|
SEM INTERVENÇÃO
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Chronic thrombo-embolic disease (CTED) prevalence
Prazo: 3 to 6 months after pulmonary embolism
|
CTED is determined by lung ventilation-perfusion scintigraphy witch detect a persistant obstruction more than 10% of the pulmonary arteries perfusion (defined by amputation of at least two pulmonary segments on V/ Q lung scan).
|
3 to 6 months after pulmonary embolism
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Associated risk factors for CTED occurrence
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: (age, BMI, D-dimer level, clinical severity-PESI score, diameter of the right ventricle on ultrasound (mm), quality ofsystolic function right ventricle on ultrasound, thrombolytic treatment, size of the pulmonary artery trunk, unprovoked nature of VTE, time between onset of symptoms and diagnosis) global clinical Data in the medical document
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence BMI
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: BMI (kg / m²)
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence D-dimer level
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: D-dimer level (ng / ml) on arrival
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence clinical severity
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: clinical severity according to ESC criteria
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence ultrasound parameters of RV function
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: clinical severity: ultrasound parameters of RV function
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence diameter of the pulmonary artery trunk
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: clinical severity: diameter of the pulmonary artery trunk (mm) measured on ultrasound and / or CT scan
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence need for thrombolytic therapy or infusion of inotropic agent
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: clinical severity: need for thrombolytic therapy or infusion of inotropic agent at the physician's discretion
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence unprovoked nature of the event
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: clinical severity: unprovoked nature of the event at the physician's discretion
|
3 to 6 months after pulmonary embolism
|
Associated risk factors for CTED occurrence time between onset of symptoms and diagnosis
Prazo: 3 to 6 months after pulmonary embolism
|
The initial risk factors are the classic cardiologic data: time between onset of symptoms and diagnosis (days)
|
3 to 6 months after pulmonary embolism
|
Associated risk factors (deep vein thrombosis ) for CTED prevalence
Prazo: 3 to 6 months after pulmonary embolism
|
Number of patient with a persistence of a DVT and the persistence of deep vein thrombosis (The persistence of DVT being defined by the presence of a venous thrombus of the same location as that of the initial episode) Measurement of the level of CTED according to the persistence of deep vein thrombosis beyond diagnosis. The persistence of a DVT is defined by the presence at 3 or 6 months of a venous thrombus of the same location as the initial episode, among the patients who presented with a PE associated with a DVT. |
3 to 6 months after pulmonary embolism
|
Associated risk factors (new episode of PE or DVT ) for CTED occurrence
Prazo: 3 to 6 months after pulmonary embolism
|
Number of patients (with or without CTED) with a recurrence (new episode of PE or DVT) Recurrence of VTE is defined by defined by a new documented thromboembolic event with a non-normal d-dimers level.
|
3 to 6 months after pulmonary embolism
|
Associated risk factors (clinical presumption of CTED ) for CTED occurrence
Prazo: 3 to 6 months after pulmonary embolism
|
Agreement between the clinical presumption of CTED by an experienced physician (questioning and evaluation of dyspnea) compared to the diagnosis of CTED by lung scintigraphy.
The clinical presumption by the clinician (presence or not of an CTED) is based on the questioning, the clinical examination and the realization of an echocardiography, if necessary, in order to rule out pulmonary hypertension.
|
3 to 6 months after pulmonary embolism
|
quality of life score
Prazo: 3 to 6 months after pulmonary embolism
|
Assessment of quality of life using the PembQOL score
|
3 to 6 months after pulmonary embolism
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 21Cardio02
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em SEM INTERVENÇÃO
-
University of TurkuDesconhecidoSaudável | Comportamento de saúdeFinlândia
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgDesconhecidoInfarto CerebralAlemanha
-
Henry Ford Health SystemBlue Cross Blue Shield of Michigan FoundationConcluído
-
Northwestern UniversityEmory UniversityConcluídoAfasia Progressiva Primária | Esgotamento do cuidadorEstados Unidos
-
Rhode Island HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...ConcluídoCyberbullyingEstados Unidos
-
University of VirginiaConcluídoLesão da medula espinal | Úlceras de pressãoEstados Unidos
-
Charles G. ProberStanford University; Heidelberg University; University of Stellenbosch; University...ConcluídoAleitamento Materno Exclusivo | Práticas de alimentação infantilÁfrica do Sul
-
University of Alabama, TuscaloosaNational Institute of Nursing Research (NINR)ConcluídoDor | Cuidado paliativo | Distúrbios da Retenção Cognitiva | Outra doença crônicaEstados Unidos
-
Brigham and Women's HospitalUniversity of Colorado, DenverConcluídoDiabetes Mellitus GestacionalEstados Unidos
-
LuciLabCentre de Recherche de l'Institut Universitaire de Geriatrie de Montreal; Sojecci...ConcluídoComportamento de risco | Declínio CognitivoCanadá